Primary outcomes
LVMi ≤
REGRESSION, TYPE 2 DIABETES MELLITUS
The effect of empagliflozin on LVMi regression over 6 months was significantly different between patients with a baseline LVMi ≤ 60 g/m
Treatment with empagliflozin (10 mg/d) and 6-month change in LVMi stratified by baseline LVMi of ≤ 60 g/m*ANCOVA model adjusted for duration of type 2 diabetes mellitus, glucose (random), previous history of PCI in addition to baseline LVMi. LVMi, left ventricular mass indexed to body surface area.The 6-month change in LVMi from estimation of a fractional polynomial of baseline LVMi stratified by the treatment arm is shown in Fig. 
Treatment with empagliflozin (10 mg/d) and 6-month change in LVMi estimated over baseline LVMi values fitted to fractional-polynomial prediction with associated 95% confidence intervals. LVMi, left ventricular mass indexed to body surface area